Considering that treatment strategies based on synthetic lethality are effective in various cancers, Akt or PARP inhibitors are anticipated to exhibit efficacy in EBVaGC harbouring ARID1A mutations.100,101 These treatments targeting ARID1A-mutated or deficient tumours may be promising for EBVaGC management. The gene discussed is ARID1A; the disease is neoplasm.